COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study.
COVID-19
SACT
SARS-CoV-2
cancer
chemotherapy
coronavirus
hormone therapy
immunotherapy
novel coronavirus
oncology
systemic anti-cancer treatment
targeted treatment
tumour
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
09
2020
accepted:
15
10
2020
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
13
11
2020
Statut:
epublish
Résumé
Patients with cancer are hypothesised to be at increased risk of contracting COVID-19, leading to changes in treatment pathways in those treated with systemic anti-cancer treatments (SACT). This study investigated the outcomes of patients receiving SACT to assess whether they were at greater risk of contracting COVID-19 or having more severe outcomes. Data was collected from all patients receiving SACT in two cancer centres as part of CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London). The primary outcome was the effect of clinical characteristics on the incidence and severity of COVID-19 infection in patients on SACT. We used univariable and multivariable models to analyse outcomes, adjusting for age, gender and comorbidities. A total of 2871 patients receiving SACT from 2 March to 31 May 2020 were analysed; 68 (2.4%) were diagnosed with COVID-19. Cancer patients receiving SACT were more likely to die if they contracted COVID-19 than those who did not [adjusted (adj.) odds ratio (OR) 9.84; 95% confidence interval (CI) 5.73-16.9]. Receiving chemotherapy increased the risk of developing COVID-19 (adj. OR 2.99; 95% CI = 1.72-5.21), with high dose chemotherapy significantly increasing risk (adj. OR 2.36, 95% CI 1.35-6.48), as did the presence of comorbidities (adj. OR 2.29; 95% CI 1.19-4.38), and having a respiratory or intrathoracic neoplasm (adj. OR 2.12; 95% CI 1.04-4.36). Receiving targeted treatment had a protective effect (adj. OR 0.53; 95% CI 0.30-0.95). Treatment intent (curative Patients on SACT are more likely to die if they contract COVID-19. Those on chemotherapy, particularly high dose chemotherapy, are more likely to contract COVID-19, while targeted treatment appears to be protective.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with cancer are hypothesised to be at increased risk of contracting COVID-19, leading to changes in treatment pathways in those treated with systemic anti-cancer treatments (SACT). This study investigated the outcomes of patients receiving SACT to assess whether they were at greater risk of contracting COVID-19 or having more severe outcomes.
METHODS
METHODS
Data was collected from all patients receiving SACT in two cancer centres as part of CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London). The primary outcome was the effect of clinical characteristics on the incidence and severity of COVID-19 infection in patients on SACT. We used univariable and multivariable models to analyse outcomes, adjusting for age, gender and comorbidities.
RESULTS
RESULTS
A total of 2871 patients receiving SACT from 2 March to 31 May 2020 were analysed; 68 (2.4%) were diagnosed with COVID-19. Cancer patients receiving SACT were more likely to die if they contracted COVID-19 than those who did not [adjusted (adj.) odds ratio (OR) 9.84; 95% confidence interval (CI) 5.73-16.9]. Receiving chemotherapy increased the risk of developing COVID-19 (adj. OR 2.99; 95% CI = 1.72-5.21), with high dose chemotherapy significantly increasing risk (adj. OR 2.36, 95% CI 1.35-6.48), as did the presence of comorbidities (adj. OR 2.29; 95% CI 1.19-4.38), and having a respiratory or intrathoracic neoplasm (adj. OR 2.12; 95% CI 1.04-4.36). Receiving targeted treatment had a protective effect (adj. OR 0.53; 95% CI 0.30-0.95). Treatment intent (curative
CONCLUSION
CONCLUSIONS
Patients on SACT are more likely to die if they contract COVID-19. Those on chemotherapy, particularly high dose chemotherapy, are more likely to contract COVID-19, while targeted treatment appears to be protective.
Identifiants
pubmed: 33178336
doi: 10.1177/1758835920971147
pii: 10.1177_1758835920971147
pmc: PMC7592172
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920971147Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: NJH reports grants from CRUK Clinical Trial Fellowship, outside the submitted work. VEC, WW, TAF, SD, JB, KK, DH, KKS, RK, NC, MD, EB, JB, MF and DH have no conflicts of interest to disclose.
Références
Br J Haematol. 2020 Aug;190(3):336-345
pubmed: 32559308
Ann Oncol. 2020 Aug;31(8):1065-1074
pubmed: 32442581
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32611687
J Infect. 2020 Dec;81(6):e22-e24
pubmed: 32711041
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
J Clin Oncol. 2020 Oct 20;38(30):3538-3546
pubmed: 32795225
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2224-2230
pubmed: 32687551
BMC Med. 2020 Jun 9;18(1):182
pubmed: 32517687
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Cancer Discov. 2020 Jul 31;:
pubmed: 32737082
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Eur J Cancer. 2020 Aug;135:251-259
pubmed: 32540204
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Ther Adv Med Oncol. 2020 Sep 14;12:1758835920956803
pubmed: 32968429
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Lancet Oncol. 2020 Jul;21(7):904-913
pubmed: 32479787
Nat Rev Clin Oncol. 2020 Jul;17(7):386-388
pubmed: 32424196
Ann Oncol. 2020 Aug;31(8):1088-1089
pubmed: 32330541